Latest Articles
Limited utility of subendometrial enhancement in assessing the interface between the endometrium and myometrium - Nature.com
Limited utility of subendometrial enhancement in assessing the interface between the endometrium and myometrium Nature.com
Published: Oct. 14, 2024, 4:50 a.m.
MSK Endometrial Cancer e-Tumor Board - Medscape
MSK Endometrial Cancer e-Tumor Board Medscape
Published: July 12, 2024, 7 a.m.
Ultrasound Screening Often Misses Endometrial Cancer in Black Females - Healthline
Ultrasound Screening Often Misses Endometrial Cancer in Black Females Healthline
Published: July 9, 2024, 7 a.m.
The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer - Medpage Today
The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer Medpage Today
Published: July 5, 2024, 7 a.m.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer - OncLive
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer OncLive
Published: July 3, 2024, 7 a.m.
Transvaginal ultrasonography unreliable in identifying endometrial cancer for Black women - Healio
Transvaginal ultrasonography unreliable in identifying endometrial cancer for Black women Healio
Published: July 3, 2024, 7 a.m.
DKK1 loss promotes endometrial fibrosis via autophagy and exosome-mediated macrophage-to-myofibroblast transition - Journal of Translational Medicine
DKK1 loss promotes endometrial fibrosis via autophagy and exosome-mediated macrophage-to-myofibroblast transition Journal of Translational Medicine
Published: July 3, 2024, 7 a.m.
Durvalumab-Based Regimen Improves Overall Response Rate in Endometrial Cancer - www.oncnursingnews.com/
Durvalumab-Based Regimen Improves Overall Response Rate in Endometrial Cancer www.oncnursingnews.com/
Published: July 2, 2024, 7 a.m.
Ultrasound May Be Unreliable in Spotting Endometrial Cancer in Black Women - HealthDay
Ultrasound May Be Unreliable in Spotting Endometrial Cancer in Black Women HealthDay
Published: July 2, 2024, 7 a.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive
Published: July 1, 2024, 7 a.m.
Link copied to clipboard!